MedPath

Methylnaltrexone

Generic Name
Methylnaltrexone
Brand Names
Relistor
Drug Type
Small Molecule
Chemical Formula
C21H26NO4
CAS Number
916055-93-1
Unique Ingredient Identifier
0RK7M7IABE
Background

Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.

Indication

Treatment of opioids induced constipation in palliative patients that are inadequately responding to laxative therapy.

Associated Conditions
Opioid Induced Constipation (OIC)
Clinical Trials
Related News

Open-Label Treatment Extension of Protocol MNTX 302

Phase 3
Completed
Conditions
Terminal Illness
Interventions
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
89
Registration Number
NCT01367613
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Open-Label Treatment Extension of Protocol MNTX 301

Phase 3
Completed
Conditions
Terminal Illness
Interventions
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
27
Registration Number
NCT01367600
Locations
🇺🇸

Progenics Pharmaceuticals, Tarrytown, New York, United States

Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus

Phase 2
Completed
Conditions
Postoperative Ileus
Interventions
Drug: Placebo
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
65
Registration Number
NCT01367548
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
6
Registration Number
NCT01367496
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

Phase 1
Completed
Conditions
Healthy Male Volunteers
Interventions
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
6
Registration Number
NCT01367483
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone

Phase 2
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
12
Registration Number
NCT01367587
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Phase 1
Completed
Conditions
Healthy Adults
Interventions
Drug: SC Placebo
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
54
Registration Number
NCT01367535
Locations
🇺🇸

Progenics Pharmaceuticals, Tarrytown, New York, United States

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function

Phase 1
Completed
Conditions
Liver Dysfunction
Interventions
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
24
Registration Number
NCT01367522
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Phase 2
Completed
Conditions
Bowel Dysfunction
Interventions
First Posted Date
2011-06-07
Last Posted Date
2019-11-27
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
39
Registration Number
NCT01367574
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

Phase 1
Completed
Conditions
Healthy Males
Interventions
Drug: Placebo
First Posted Date
2011-06-07
Last Posted Date
2023-04-12
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
15
Registration Number
NCT01367561
Locations
🇺🇸

Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy